Gossamer Bio (GOSS) Equity Average (2022 - 2025)
Gossamer Bio's Equity Average history spans 4 years, with the latest figure at -$102.5 million for Q4 2025.
- For Q4 2025, Equity Average fell 345.24% year-over-year to -$102.5 million; the TTM value through Dec 2025 reached -$102.5 million, down 345.24%, while the annual FY2025 figure was -$46.6 million, 201.09% down from the prior year.
- Equity Average reached -$102.5 million in Q4 2025 per GOSS's latest filing, down from -$64.2 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $83.7 million in Q4 2023 to a low of -$102.5 million in Q4 2025.
- Average Equity Average over 4 years is $9.3 million, with a median of $19.9 million recorded in 2022.
- Peak YoY movement for Equity Average: plummeted 766.2% in 2023, then soared 646.38% in 2024.
- A 4-year view of Equity Average shows it stood at $34.2 million in 2022, then soared by 144.62% to $83.7 million in 2023, then plummeted by 50.04% to $41.8 million in 2024, then crashed by 345.24% to -$102.5 million in 2025.
- Per Business Quant, the three most recent readings for GOSS's Equity Average are -$102.5 million (Q4 2025), -$64.2 million (Q3 2025), and -$26.2 million (Q2 2025).